NEW YORK-Shortness of breath, pain, and fatigue are among the most common symptoms in patients with advanced lung cancer. An oncology nurse whose practice is exclusively patients with thoracic malignancies discussed the management of symptoms and side effects of lung cancer and the importance of assessment in this setting at a Cancer Care, Inc. teleconference for health care professionals.
NEW YORKShortness of breath, pain, and fatigue are among the most common symptoms in patients with advanced lung cancer. An oncology nurse whose practice is exclusively patients with thoracic malignancies discussed the management of symptoms and side effects of lung cancer and the importance of assessment in this setting at a Cancer Care, Inc. teleconference for health care professionals.
"Our patients come to us most commonly complaining of shortness of breath or dyspnea," said Ann Steagall, RN, BSN, OCN, clinical nurse coordinator, Thoracic Oncology Program, University of North Carolina at Chapel Hill. This symptom can be caused by the disease or may be treatment related, she added.
"Certainly, if disease occludes an airway or causes collapse of the lung, patients will have a shortness of breath. And disease that causes a pleural effusion also causes dyspnea." Chemotherapy and/or radiation therapy are good modalities for helping with this symptom, she said, and a pleural effusion can be treated with thoracentesis, but if these symptoms are treatment related, they may not be reversible.
"When pulmonary symptoms are related to radiation or to chemotherapy, some patients respond to steroids, but others do not. Most patients who have end-stage disease eventually will use oxygen therapy, she said, but her unit also teaches positioning, breathing techniques, and other ways to cope with a nonreversible dyspnea.
As is generally known, Ms. Steagall added, oxygen therapy is not the definitive therapy in these patients. "I work with a lot of hospice agencies, and patients who are in the terminal phase of their lung cancer generally have severe shortness of breath. In these patients, we tend to use narcotics and, even more recently, aerosol morphine."
Chest Pain
Pain is an issue for lung cancer patients as it is for all cancer patients, but the chest pain in lung cancer patients can sometimes be mistaken for cardiac painand cardiac involvement has to be ruled out. When the cause is due to the primary tumor or metastases, chemotherapy and/or radiation therapy can usually help the pain by decreasing the tumor size, but, in the interim, patients receive narcotic pain management, Ms. Steagall said.
To institute the best pain management treatment, the oncology nurse should do a very careful pain assessment. Ms. Steagall said that she prefers questioning her patients about their pain rather than using a pain assessment tool. "I like to askWhat is your pain like? Where does it seem to be coming from? What does it limit you in doing?" she said.
The best pain management plan, she said, might be a sustained-release narcotic like oxycodone (OxyContin) or a sustained-release morphine, with a shorter-acting drug used to manage breakthrough pain.
Many lung cancer patients get to the point where they can’t swallow. "The fentanyl patch (Duragesic) is another good option for patients who cannot swallow pills or need a change in drug," she said.
With terminal patients, she recommended use of elixirs. "I explain to family members how they can just put the elixir on the mucous membrane where it is absorbed, so the patient doesn’t have to swallow." When family members give the elixir to the patient, she added, it helps them to feel that they are helping make the patient more comfortable.
With the use of taxanes, many lung cancer patients are getting peripheral neuropathies. The pathophysiology is not well understood, Ms. Steagall said, "but we do know that this is one of the dose-limiting, if not the dose-limiting, toxicity of taxanes." She said that glutamine is being used to reduce these treatment-related neuropathies. "If the patient is given 10 g of glutamine three time a day for the first 5 days of a chemotherapy cycle, the neuropathies may at least be delayed and, in most cases, are reduced, and this seems also to reduce the arthralgia and myalgia that occur with the taxanes," she said.
Noting that some patients tend not to tell their physician about side effects, out of fear that the drug dosage will be reduced, Ms. Steagall urged oncology nurses to carefully check for signs of neurotoxicity (see Table).
Checking for Neuropathy
After Chemotherapy:
Questions to Ask the Patient
Are you noticing any changes in your handwriting?
Is it more difficult to write?
Are you having difficulty buttoning your buttons or holding on to a zipper?
Are you having problems holding your fork?
Are you noticing that you’re stumbling when going up steps or stepping up to a curb?
The platinum compounds have been known for many years to cause ototoxicity. This is usually a reversible symptom, though not always, she said. In many instances, just lowering the dose or stopping the drug can help.
Fatigue is one of the most common symptoms that cancer patients complain about, Ms. Steagall said, "maybe even more so than pain and definitely more than the neuropathies." It can be a dose-limiting toxicity, and some patients even refuse further chemotherapy due to the effect on their quality of life, she said.
Anemia is one possible cause of fatigue in cancer patients. When anemia is drug induced, it can be corrected with drugs, she noted, "but I think it is important to consider other factors."
One factor that patients seldom consider is inactivity. "When patients are under stress, they’re very anxious, not sleeping, and not eating properly, and all of this can enhance the feeling of fatigue," she said. It is also important to tell patients up front that they will have fatigue. If they don’t know to expect fatigue, it can be more anxiety producing when it occurs.
To help cope with fatigue, patients can be taught to conserve their energy and to prioritize the jobs they have to do.
Anorexia affects about 60% of cancer patients. Lung cancer patients tend to have this symptom by the time they are diagnosed. "Most of our patients are smokers," Ms. Steagall said. "They may already have smoking-related alterations in taste that are enhanced by their disease and by their therapy, she said. Alterations in taste can actually lead to changes in the digestive system, she said. Digestive enzyme levels may be decreased, which may prolong the entire act of digestion.
Some patients who have severe problems may need a feeding tube, short or long term, she said.
Emotional Issues
Winfield Boerckel, CSW, a Cancer Care information support systems coordinator and a lung cancer support group facilitator, said that lung cancer patients often have emotional issues related to their cancer. If the patients were smokers, they are often ashamed and angry at themselves, he said. They may also be angry at the tobacco companies. They may have to deal with the anger and "I told you so’s" of their family. Patients who were not smokers are afraid that others will think they were smokers.
Support groups, whether in person, on the phone, or on the Internet, are crucial in helping patients vent these feelings and find solutions, Mr. Boerckel said.
He pointed out that the physician is generally not the right person from whom to seek emotional support. "It is important to see physicians as being there to provide information and treatment," he said. There are others on the health care team that can provide emotional support. "Communications with the physician should focus on getting information about disease and treatment," he said.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.